• Publications
  • Influence
Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
Background and aims: Obese and diabetic mice display enhanced intestinal permeability and metabolic endotoxaemia that participate in the occurrence of metabolic disorders. Our recent data support theExpand
  • 1,685
  • 69
  • PDF
The endocannabinoid system links gut microbiota to adipogenesis
Obesity is characterised by altered gut microbiota, low‐grade inflammation and increased endocannabinoid (eCB) system tone; however, a clear connection between gut microbiota and eCB signalling hasExpand
  • 424
  • 23
  • PDF
Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.
The CB(1) and CB(2) cannabinoid receptors are G protein-coupled receptors (GPCRs) recognized by a variety of endogenous ligands and activating multiple signalling pathways. This multiplicity ofExpand
  • 168
  • 14
  • PDF
The palmitoylethanolamide family: a new class of anti-inflammatory agents?
The discovery of anandamide as an endogenous ligand for the cannabinoid receptors has led to a resurgence of interest in the fatty acid amides. However, N-palmitoylethanolamine (PEA), a shorter andExpand
  • 257
  • 13
  • PDF
Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid Signaling
2‐Arachidonoylglycerol plays a major role in endocannabinoid signaling, and is tightly regulated by the monoacylglycerol lipase (MAGL). Here we report the crystal structure of human MAGL. The proteinExpand
  • 133
  • 13
  • PDF
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
The endocannabinoid system : drug targets, lead compounds, and potential therapeutic applications.
  • 289
  • 9
  • PDF
Increasing endogenous 2‐arachidonoylglycerol levels counteracts colitis and related systemic inflammation
Inflammatory bowel diseases (IBDs) are chronic inflammatory conditions for which new therapeutic approaches are needed. Genetic and pharmacological data point to a protective role of CB1 and CB2Expand
  • 141
  • 9
  • PDF
Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide
The ability of a series of homologues and analogues of palmitoylethanolamide to inhibit the uptake and fatty acid amidohydrolase (FAAH)‐catalysed hydrolysis of [3H]‐anandamide ([3H]‐AEA) has beenExpand
  • 151
  • 8
  • PDF
A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling.
Together with anandamide, 2-arachidonoylglycerol (2-AG) constitutes one of the main representatives of a family of endogenous lipids known as endocannabinoids. These act by binding to CB(1) and CB(2)Expand
  • 87
  • 8
  • PDF
‘Entourage’ effects of N‐acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide‐induced vanilloid receptor activation and upon anandamide metabolism
The abilities of a series of saturated N‐acyl ethanolamines and related compounds to affect the ability of anandamide (AEA) to produce a Ca2+ influx into human embryonic kidney cells expressing theExpand
  • 132
  • 7